Literature DB >> 15690231

QT interval prolongation associated with the oral use of domperidone in an infant.

C M G Rocha1, M M Barbosa.   

Abstract

Gastroesophageal reflux is very common in childhood. If conservative procedures fail to relieve it, the use of a potent antiemetic agent that facilitates gastric motility and emptying, such as domperidone, is justified. We report a 4-month-old child who presented with QT interval prolongation after the oral use of domperidone, which normalized after the drug was discontinued.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15690231     DOI： 10.1007/s00246-004-0922-z

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN： 0172-0643            Impact factor:   1.655


  11 in total

Review 1.  Gastroesophageal reflux disease in children: an overview of pathophysiology, diagnosis, and treatment.

Authors:  David A Gremse
Journal:  J Pediatr Gastroenterol Nutr       Date:  2002       Impact factor: 2.839

2.  Q-T interval prolongation and ventricular fibrillation with i.v. domperidone.

Authors:  E Bruera; R Villamayor; E Roca; M Barugel; J Tronge; R Chacon
Journal:  Cancer Treat Rep       Date:  1986-04

3.  Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone.

Authors:  G Giaccone; O Bertetto; A Calciati
Journal:  Lancet       Date:  1984-12-08       Impact factor: 79.321

Review 4.  Gastroesophageal reflux in children. Clinical manifestations, diagnosis, and therapy.

Authors:  M Glassman; D George; B Grill
Journal:  Gastroenterol Clin North Am       Date:  1995-03       Impact factor: 3.806

5.  Cardiac arrest after treatment with intravenous domperidone.

Authors:  J B Roussak; P Carey; H Parry
Journal:  Br Med J (Clin Res Ed)       Date:  1984-12-08

Review 6.  Domperidone: a peripherally acting dopamine2-receptor antagonist.

Authors:  J A Barone
Journal:  Ann Pharmacother       Date:  1999-04       Impact factor: 3.154

7.  Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders.

Authors:  B Drolet; G Rousseau; P Daleau; R Cardinal; J Turgeon
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

8.  Domperidone plus magnesium hydroxide and aluminum hydroxide: a valid therapy in children with gastroesophageal reflux. A double-blind randomized study versus placebo.

Authors:  A Carroccio; G Iacono; G Montalto; F Cavataio; M Soresi; A Notarbartolo
Journal:  Scand J Gastroenterol       Date:  1994-04       Impact factor: 2.423

9.  Cisapride-induced long QT interval.

Authors:  M B Lewin; R M Bryant; A L Fenrich; R G Grifka
Journal:  J Pediatr       Date:  1996-02       Impact factor: 4.406

10.  Cardiac arrhythmias during cytotoxic chemotherapy: role of domperidone.

Authors:  R J Osborne; M L Slevin; R W Hunter; J Hamer
Journal:  Hum Toxicol       Date:  1985-11
View more
  16 in total

Review 1.  Domperidone-Associated QT Interval Prolongation in Non-oncologic Pediatric Patients: A Review of the Literature.

Authors:  Amy D Morris; Jennifer Chen; Elaine Lau; Jennifer Poh
Journal:  Can J Hosp Pharm       Date:  2016-06-30

Review 2.  Gastroesophageal reflux disease in children and adolescents: when and how to treat.

Authors:  Matthew W Carroll; Kevan Jacobson
Journal:  Paediatr Drugs       Date:  2012-04-01       Impact factor: 3.022

Review 3.  Domperidone-associated sudden cardiac death in the general population and implications for use in patients undergoing hemodialysis: a literature review.

Authors:  Joy Makari; Karen Cameron; Marisa Battistella
Journal:  Can J Hosp Pharm       Date:  2014-11

4.  Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects.

Authors:  Henry P Parkman; Michael R Jacobs; Anurag Mishra; Jessica A Hurdle; Priyanka Sachdeva; John P Gaughan; Evgeny Krynetskiy
Journal:  Dig Dis Sci       Date:  2010-11-10       Impact factor: 3.199

5.  Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance.

Authors:  Luigi X Cubeddu
Journal:  Curr Cardiol Rev       Date:  2009-08

Review 6.  Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review.

Authors:  Shlomi Cohen; Mirjam Bueno de Mesquita; Francis B Mimouni
Journal:  Br J Clin Pharmacol       Date:  2015-06-11       Impact factor: 4.335

Review 7.  Domperidone and Risk of Ventricular Arrhythmia and Cardiac Death: A Systematic Review and Meta-analysis.

Authors:  Nattawut Leelakanok; Andrea Holcombe; Marin L Schweizer
Journal:  Clin Drug Investig       Date:  2016-02       Impact factor: 2.859

8.  Current use of domperidone and co-prescribing of medications that increase its arrhythmogenic potential among older adults: a population-based cohort study in Ontario, Canada.

Authors:  Carlos Rojas-Fernandez; Anne L Stephenson; Hadas D Fischer; Xuesong Wang; Tiago Mestre; Janine R Hutson; Margarita Pondal; Douglas S Lee; Paula A Rochon; Connie Marras
Journal:  Drugs Aging       Date:  2014-11       Impact factor: 3.923

9.  Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Authors:  Rachel Rosen; Yvan Vandenplas; Maartje Singendonk; Michael Cabana; Carlo DiLorenzo; Frederic Gottrand; Sandeep Gupta; Miranda Langendam; Annamaria Staiano; Nikhil Thapar; Neelesh Tipnis; Merit Tabbers
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-03       Impact factor: 2.839

10.  Effect of domperidone on the QTc interval in premature infants.

Authors:  A Günlemez; A Babaoğlu; A E Arisoy; G Türker; A S Gökalp
Journal:  J Perinatol       Date:  2009-07-23       Impact factor: 2.521
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.